A citation-based method for searching scientific literature

Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni, Hiroshi Hiai, Wataru Mizunoya, Tohru Fushiki, Jens Juul Holst, Mitsuhiro Makino, Akira Tashita, Yukari Kobara, Yoshiharu Tsubamoto, Takayoshi Jinnouchi, Takahito Jomori, Yutaka Seino. Nat Med 2002
Times Cited: 610



Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell, Uma Kuchibhotla, Julie S Moyers, Charles T Benson, Ruth E Gimeno, David A D'Alessio, Axel Haupt. Mol Metab 2018
Times Cited: 120




List of shared articles



Times cited




Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective.
Joanna Michałowska, Ewa Miller-Kasprzak, Paweł Bogdański. Nutrients 2021
3

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists.
Aaron Novikoff, Shannon L O'Brien, Miriam Bernecker, Gerald Grandl, Maximilian Kleinert, Patrick J Knerr, Kerstin Stemmer, Martin Klingenspor, Anja Zeigerer, Richard DiMarchi,[...]. Mol Metab 2021
4

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Qian Zhang, Challa Tenagne Delessa, Robert Augustin, Mostafa Bakhti, Gustav Colldén, Daniel J Drucker, Annette Feuchtinger, Cristina Garcia Caceres, Gerald Grandl, Alexandra Harger,[...]. Cell Metab 2021
12

Old Paradoxes and New Opportunities for Appetite Control in Obesity.
Léa Montégut, Carlos Lopez-Otin, Christophe Magnan, Guido Kroemer. Trends Endocrinol Metab 2021
2

Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
Jason A West, Anastasia Tsakmaki, Soumitra S Ghosh, David G Parkes, Rikke V Grønlund, Philip J Pedersen, David Maggs, Harith Rajagopalan, Gavin A Bewick. PLoS One 2021
1

Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion.
Van B Lu, Fiona M Gribble, Frank Reimann. Nutrients 2021
3

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
Ricardo J Samms, Michael E Christe, Kyla Al Collins, Valentina Pirro, Brian A Droz, Adrienne K Holland, Jessica L Friedrich, Samantha Wojnicki, Debra L Konkol, Richard Cosgrove,[...]. J Clin Invest 2021
2

Gut peptide regulation of food intake - evidence for the modulation of hedonic feeding.
Orla R M Woodward, Fiona M Gribble, Frank Reimann, Jo E Lewis. J Physiol 2021
0

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea.
Matthew R Hayes, Tito Borner, Bart C De Jonghe. Diabetes 2021
1

GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Basedz Therapies in Treating Metabolic Disorders.
Ricardo J Samms, Kyle W Sloop, Fiona M Gribble, Frank Reimann, Alice E Adriaenssens. Diabetes 2021
1

Treatment of type 2 diabetes: challenges, hopes, and anticipated successes.
Michael A Nauck, Jakob Wefers, Juris J Meier. Lancet Diabetes Endocrinol 2021
1

Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
Tito Borner, Ian C Tinsley, Robert P Doyle, Matthew R Hayes, Bart C De Jonghe. Br J Pharmacol 2021
0

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys.
Shu-Chen Lu, Michelle Chen, Larissa Atangan, Elizabeth A Killion, Renee Komorowski, Yuan Cheng, Chawita Netirojjanakul, James R Falsey, Marina Stolina, Denise Dwyer,[...]. Cell Rep Med 2021
0

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A Killion, Shu-Chen Lu, Madeline Fort, Yuichiro Yamada, Murielle M Véniant, David J Lloyd. Endocr Rev 2020
19

Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors.
Rie Suzuki, Giles A Brown, John A Christopher, Conor C G Scully, Miles Congreve. J Med Chem 2020
9




Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review.
Maria Buur Nordskov Gabe, Wijnand J C van der Velden, Florent Xavier Smit, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde. Peptides 2020
7

Leveraging the Gut to Treat Metabolic Disease.
Ruth E Gimeno, Daniel A Briere, Randy J Seeley. Cell Metab 2020
16

How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J Samms, Matthew P Coghlan, Kyle W Sloop. Trends Endocrinol Metab 2020
23

Incretins in obesity and diabetes.
Chee W Chia, Josephine M Egan. Ann N Y Acad Sci 2020
19


Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.
Patrick J Knerr, Stephanie A Mowery, Brian Finan, Diego Perez-Tilve, Matthias H Tschöp, Richard D DiMarchi. Peptides 2020
10

Recent advances of GIP and future horizons.
Jens Juul Holst, Mette Marie Rosenkilde. Peptides 2020
6

Obesity medications in development.
Candida J Rebello, Frank L Greenway. Expert Opin Investig Drugs 2020
8

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
Natasha C Bergmann, Lærke S Gasbjerg, Sebastian M Heimbürger, Liva S L Krogh, Flemming Dela, Bolette Hartmann, Jens J Holst, Lene Jessen, Mikkel B Christensen, Tina Vilsbøll,[...]. Diabetes Care 2020
12

Gut Hormone GIP Induces Inflammation and Insulin Resistance in the Hypothalamus.
Yukiko Fu, Kentaro Kaneko, Hsiao-Yun Lin, Qianxing Mo, Yong Xu, Takayoshi Suganami, Peter Ravn, Makoto Fukuda. Endocrinology 2020
6


Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.
Christoffer Clemmensen, Brian Finan, Timo D Müller, Richard D DiMarchi, Matthias H Tschöp, Susanna M Hofmann. Nat Rev Endocrinol 2019
44

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
60

Function and mechanisms of enteroendocrine cells and gut hormones in metabolism.
Fiona M Gribble, Frank Reimann. Nat Rev Endocrinol 2019
119

Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives.
Mar Quiñones, Johan Fernø, Carlos Diéguez, Ruben Nogueiras, Omar Al-Massadi. Expert Opin Drug Discov 2019
8